EUVIMEDObjevte EUVIMED
Video/Audio

Expression, Clinical Significance, and Role in Immunotherapy Efficacy Evaluation of the Co-stimulatory Molecule LLT1 in Gastric Cancer

Feng Zhang, Hao Zhang, Jinjing Xu, Ruipeng Wang, Hanqin Xuan, Shenghua Zhan, Lei Cao, Ling Gao

Journal of Visualized Experiments · 2025

DOI: 10.3791/68827 ↗

At a glance

Video/Audio in Journal of Visualized Experiments, 2025. Written by Feng Zhang and 7 co-authors. Institution: Department of General Surgery, The First Affiliated Hospital of Soochow University. Major MEDLINE topics: Stomach Neoplasms, Immunotherapy, Adenocarcinoma. 50 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

LLT1 is a novel immune checkpoint molecule and potential therapeutic target. Immunotherapy has improved outcomes in advanced gastric cancer; however, many patients do not respond or develop resistance, and predictive biomarkers are lacking. The role of LLT1 in gastric cancer immune evasion and its effect on immunotherapy response remain unclear. To assess this, LLT1 expression was analyzed in the Cancer Genome Atlas (TCGA) gastric adenocarcinoma dataset using multiple algorithms (TIMER, CIBERSORT, and ESTIMATE) to quantify immune cell infiltration. Protein expression was validated by immunohistochemistry (IHC) in 268 gastric adenocarcinoma samples and by multiplex immunofluorescence (MIF) in 115 post-immunotherapy tissues. Integrated transcriptomic and proteomic data were analyzed for associations with tumor microenvironment features and clinical immunotherapy outcomes. The results showed that high LLT1 protein expression was significantly associated with less advanced tumor characteristics (lower invasion depth and nodal metastasis; P < 0.05) and longer overall survival (P = 0.012). LLT1 mRNA and protein levels correlated with greater CD8+ T-cell and M1 macrophage infiltration and elevated PD-L1 expression in the tumor microenvironment. Among the first cohort of 198 patients with available prognostic data, patients with high LLT1 expression (n=117) demonstrated significantly longer overall survival compared to those with low expression (n=81). In the second cohort of patients treated with combined immunotherapy and chemotherapy, tumors with high LLT1 expression (n=48) had longer progression-free survival (P = 0.014) than those with low LLT1 expression (n=67). A significant increase (P < 0.05) in PD-1+CD161+ immune cell populations was observed in Immunotherapy-effective patients (n=62) relative to treatment-resistant patients (n=53). Conclusively, LLT1 expression is a promising biomarker of a favorable prognosis in gastric cancer. To our knowledge, this is the first study to demonstrate that LLT1 expression predicts improved response to combined chemotherapy and immunotherapy in gastric cancer, supporting its potential in guiding immunotherapeutic strategies.

Subjects

MeSH terms (MEDLINE)

Stomach NeoplasmsImmunotherapyAdenocarcinomaHumansFemaleMaleTumor MicroenvironmentMiddle AgedBiomarkers, TumorAgedClinical Relevance

Substances

Biomarkers, Tumor

Authors and institutions

  • Department of General Surgery, The First Affiliated Hospital of Soochow University.
  • Department of Pathology, The First Affiliated Hospital of Soochow University.
  • Department of Pathology, The First Affiliated Hospital of Soochow University; zhanshenghua@suda.edu.cn.
  • Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University; Jiangsu Key Laboratory of Clinical Immunology, Soochow University; Jiangsu Key Laboratory of Gastrointestinal Tumor Immunolo…
  • Department of General Surgery, The First Affiliated Hospital of Soochow University; gaoling02@suda.edu.cn.

Cite

APA

Zhang, F., Zhang, H., Xu, J., Wang, R., Xuan, H., Zhan, S., Cao, L., & Gao, L. (2025). Expression, Clinical Significance, and Role in Immunotherapy Efficacy Evaluation of the Co-stimulatory Molecule LLT1 in Gastric Cancer. Journal of Visualized Experiments. https://doi.org/10.3791/68827

Vancouver

Zhang F, Zhang H, Xu J, Wang R, Xuan H, Zhan S, et al. Expression, Clinical Significance, and Role in Immunotherapy Efficacy Evaluation of the Co-stimulatory Molecule LLT1 in Gastric Cancer. Journal of Visualized Experiments. 2025. doi:10.3791/68827

BibTeX
@article{Zhang2025,
  author = {Zhang, Feng and Zhang, Hao and Xu, Jinjing and Wang, Ruipeng and Xuan, Hanqin and Zhan, Shenghua and Cao, Lei and Gao, Ling},
  title = {Expression, Clinical Significance, and Role in Immunotherapy Efficacy Evaluation of the Co-stimulatory Molecule LLT1 in Gastric Cancer},
  journal = {Journal of Visualized Experiments},
  year = {2025},
  doi = {10.3791/68827}
}
Start for free →